The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Evaluating the FDA Approval of taletrectinib for ROS+ NSCLC
Geoffrey Liu, MD, University of Toronto, Toronto, Canada, comments on the emerging role of taletrectinib in the treatment of ROS1 positive patients with non-small cell lung cancer (NSCLC) following its FDA approval in June 2025. Taletrectinib is the first-line treatment of choice due to its superior efficacy and safety profile compared to other available options, and may be a suitable second-line treatment for patients who have failed crizotinib and entrectinib. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There are two main groups of patients that we will be dealing with now. First, newly diagnosed ROS1 positive patients need a first-line treatment of choice. The efficacy and the safety of taletrectinib is superior to that of repotrectinib and entrectinib, as well as that of crizotinib. So of the available drugs that are available in the U.S., I would envision that taletrectinib would become the first-line drug of choice across the board...
There are two main groups of patients that we will be dealing with now. First, newly diagnosed ROS1 positive patients need a first-line treatment of choice. The efficacy and the safety of taletrectinib is superior to that of repotrectinib and entrectinib, as well as that of crizotinib. So of the available drugs that are available in the U.S., I would envision that taletrectinib would become the first-line drug of choice across the board. I’ve personally treated patients with all of these drugs, and I can affirm that the safety signal associated with taletrectinib is a much easier drug to deal with than some of the other drugs in line. In the second line setting, a similar issue is that because patients here have demonstrated efficacy post-crizotinib and post-entrectinib, that it’s a very reasonable drug to use in this particular setting, where a lot of patients have been previously diagnosed before the era of these new drugs were available and were previously on these other drugs. So at the time of failure of these drugs, I would imagine that taletrectinib would be a very good second and subsequent line of therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
